Trellis Bioscience, Inc. Discovers Anti-RSV Monoclonal Antibodies Isolated Directly from Human Blood Cells

Published: Oct 26, 2007

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Scientists from Trellis Bioscience are presenting data today on their discovery of monoclonal antibodies from human blood against a target protein of the respiratory syncytial virus (RSV). The antibodies were identified and isolated directly from the antibody producing B cells of RSV-infected patients, using a proprietary process called CellspotTM developed at Trellis. These human anti-RSV antibodies are being evaluated for therapeutic utility in animal models of RSV infection. Findings are being presented at the RSV 2007 Symposium held at Marco Island, Florida.

Back to news